The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 349:1385-1387 October 2, 2003 Number 14
NextNext

Dalteparin Compared with an Oral Anticoagulant for Thromboprophylaxis in Patients with Cancer

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Bick, R. L.
-Related Article
by Lee, A. Y.Y.
-PubMed Citation
To the Editor: Lee and colleagues (July 10 issue)1 provide strong and pertinent data indicating the benefit of prolonged treatment with low-molecular-weight heparin for the prevention of recurrent venous thromboembolism in patients with cancer. Nevertheless, among the patients who received an oral anticoagulant, the international normalized ratio (INR) was above the therapeutic range 24 percent of the time. This could be a source of bias in evaluating the effect of the coumarin derivative. In addition, we wonder whether the authors found that the number of patients with clinically relevant thrombocytopenia was higher after long-term treatment with low-molecular-weight heparin than it . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.